dual anti-CD19/anti-BAFF CAR T-cell therapy (Shanghai YaKe Biotechnology/Zhejiang University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namedual anti-CD19/anti-BAFF CAR T-cell therapy (Shanghai YaKe Biotechnology/Zhejiang University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell activating factor receptor modulatorsB-cell-activating factor/B lymphocyte stimulator modulatorsImmunosuppressants +[5] 
TargetsB-lymphocyte antigen CD19B-cell activating factor receptorB-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Yake Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Yake Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A